Targeting Mcl-1 for the therapy of cancer
Expert opinion on investigational drugs, 2011•Taylor & Francis
Introduction: Human cancers are genetically and epigenetically heterogeneous and have
the capacity to commandeer a variety of cellular processes to aid in their survival, growth
and resistance to therapy. One strategy is to overexpress proteins that suppress apoptosis,
such as the Bcl-2 family protein Mcl-1. The Mcl-1 protein plays a pivotal role in protecting
cells from apoptosis and is overexpressed in a variety of human cancers. Areas covered:
Targeting Mcl-1 for extinction in these cancers, using genetic and pharmacological …
the capacity to commandeer a variety of cellular processes to aid in their survival, growth
and resistance to therapy. One strategy is to overexpress proteins that suppress apoptosis,
such as the Bcl-2 family protein Mcl-1. The Mcl-1 protein plays a pivotal role in protecting
cells from apoptosis and is overexpressed in a variety of human cancers. Areas covered:
Targeting Mcl-1 for extinction in these cancers, using genetic and pharmacological …
Introduction: Human cancers are genetically and epigenetically heterogeneous and have the capacity to commandeer a variety of cellular processes to aid in their survival, growth and resistance to therapy. One strategy is to overexpress proteins that suppress apoptosis, such as the Bcl-2 family protein Mcl-1. The Mcl-1 protein plays a pivotal role in protecting cells from apoptosis and is overexpressed in a variety of human cancers.
Areas covered: Targeting Mcl-1 for extinction in these cancers, using genetic and pharmacological approaches, represents a potentially effectual means of developing new efficacious cancer therapeutics. Here we review the multiple strategies that have been employed in targeting this fundamental protein, as well as the significant potential these targeting agents provide in not only suppressing cancer growth, but also in reversing resistance to conventional cancer treatments.
Expert opinion: We discuss the potential issues that arise in targeting Mcl-1 and other Bcl-2 anti-apoptotic proteins, as well problems with acquired resistance. The application of combinatorial approaches that involve inhibiting Mcl-1 and manipulation of additional signaling pathways to enhance therapeutic outcomes is also highlighted. The ability to specifically inhibit key genetic/epigenetic elements and biochemical pathways that maintain the tumor state represent a viable approach for developing rationally based, effective cancer therapies.
Taylor & Francis Online